Altre lingue Traws Pharma, Inc.

Azioni

TRAW

US68232V8019

Mercato chiuso - Nasdaq Altri mercati azionari 19:00:00 03/07/2024			Variaz. 5gg	Var. 1 gen.
0,3999 ^USD	+9,56%		-9,32%	-46,37%

02/07	Traws Pharma deposita una dichiarazione di registrazione per la vendita potenziale di 128,9 milioni di azioni	MT
15/05	Traws Pharma, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Traws Pharma Files for Potential Sale of 128.9 Million Shares	02/07
Travatrelvir, an Inhibitor of SARS CoV 2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir	23/05
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate	23/05
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update	16/05
Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Traws Pharma : Targeting the RAS/RAF/PI3K pathway for CD40 induction in melanoma cells to overcome resistance to anti-PD1 immunotherapies	07/05
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	07/05
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	07/05
North American Morning Briefing : Focus Turns to -2-	04/04
Traws Pharma, Inc. Announces Chief Executive Office Changes	04/04
Traws Pharma, Inc. Announces Board Changes	04/04
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics	02/04
Traws Pharma Announces New Employee Inducement Grants	02/04
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company	02/04
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc	02/04
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.	02/04
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Traws Pharma, Inc. announced that it has received $14 million in funding from OrbiMed Advisors LLC, Torrey Pines	01/04
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024	08/03
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	12/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Traws Pharma, Inc.

Azioni

TRAW

US68232V8019

Altre lingue

Filtri